Business
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with Eli Lilly and
About this update from Abcellera Biologics Inc.
[{"type":"text","content":" VANCOUVER, British Columbia--(BUSINESS WIRE)--\nAbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover therapeutic antibodies for programs in immunology, cardiovascular disease, and neuroscience. The expansion builds upon the successful research collaboration established in March 2020, which included eight de novo programs for targets selected by Lilly and an exclusive license to AbCellera’s COVID-19 antibody program.\n\n\nAbCellera has advanced all eight programs under the original agreement, and the licensed program resulted in emergency use authorization by the U.S. Food and Drug Administration for two COVID-19 antibody therapies co-developed by the companies.\n\n\n“Lilly has been a terrific partner and is one of the most admired and innovative pharmaceutical companies in the world,\" said Carl Hansen, Ph.D., founder and CEO of AbCellera. “We are excited to deepen our partnership and potentially increase our impact on patients across multiple therapeutic areas.”\n\n\nUnder the expanded agreement, Lilly has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera has received an upfront payment, will receive research payments, and is eligible to receive downstream milestone payments and royalties on net product sales.\n\n\nAbout AbCellera Biologics Inc.\n\n\nAbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.\n\n\nAbCellera Forward-Looking Statements\n\n\nThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements ...